Yes, an interim analysis in an imaging trial CIMT, strikes me as uncommon, guess it was meant to save money. If Niaspan didn't show a meaningful effect on IMT, it makes sense to stop the trial and forget about it, if it was more effective, I assume we would have heard about it.
Market Data 
Markets 
AI
